The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: A longitudinal MRI study in relapsing-remitting multiple sclerosis patients

Acta Neurologica Scandinavica

Volumn 95, Issue 4, 1997, Pages 201-207

  Gasperini, C ^a,e   Pozzilli, C ^a   Bastianello, S ^a   Koudriavtseva, T ^a   Colleluori, A ^a   Millefiorini, E ^a   Thompson, A J ^b   Horsfield, M A ^c   Galgani, S ^d   Bozzao, L ^a   Fieschi, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

exacerbation; magnetic resonance imaging; multiple sclerosis; steroid therapy

Indexed keywords

GADOLINIUM PENTETATE; METHYLPREDNISOLONE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE;

EID: 8244222298     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1997.tb00099.x     Document Type: Article

References (23)

1. KERMODE AG, THOMPSON AJ, TOFTS PS et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990(b): 113: 1477-89.
2. MILLER DH, BARKHOF F, NAUTA JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993: 116: 1077-94.
3. HARRIS JO, FRANK JA, PATRONAS N et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials. Ann Neurol 1991: 29: 548-55.
4. THORPE JW, KIDD D, MOSELEY IF et al. Serial gadolinium enhanced MRI of the brain and spinal cord in relapsing-remitting multiple sclerosis. Neurology 1996: 46: 373-8.
5. ROSE AS, KUZMAN JW, KURTZKE JF et al. Co-operative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo. Neurology 1970: 5: 1-59.
6. COMPSTON A. Methylprednisolone and multiple sclerosis. Arch Neurol 1988: 45: 669-70.
7. DURELLI L, COCITO D, RICCIO A et al. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations. Neurology 1986: 36: 238-43.
8. THOMPSON AJ, KENNARD C, SWASH M et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapses in MS. Neurology 1989: 39: 969-71.
9. MENKEN M. Consensus and controversy in neurologic practice. The case of steroid treatment in multiple sclerosis. Arch Neurol 1989: 46: 322.
10. BECK RW, CLEARY PA, TROBF JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993: 329: 1764-9.
11. BARKHOF F, HOMMES OR, SCHELTENS P, VALK J. Quantitative MRI changes in gadolinium-DTPA enhancement after high dose intravenous methylprednisolone treatment in multiple sclerosis. Neurology 1991: 41: 1219-22.
12. MILLER DH, THOMPSON AJ, MORRISSEY SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992: 55: 450-3.
13. POZZILLI C, BASTIANELLO S, KOUDRIAVTSEVA T et al. Magnetic resonance imaging changes with recombinant human Interferon beta-1a: a short term study in relapsing -remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996: 61: 251-8.
14. WICKS D, TOFTS PS, MILLER DH et al. Volume measurements of multiple sclerosis with magnetic resonance imaging. Neuroradiology 1992: 34: 475-9.
15. GONZALES-SCARANO F, GROSSMAN RI, GALLETTA S et al. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987: 21: 300-6.
16. MILLER DH, RUDGE P, JOHNSON G et al. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988: 111: 927-39.
17. BASTIANELLO S, POZZILLI C, BERNARDI S et al. Serial study of gadolinium-DTPA MRI enhancement. Neurology 1990: 40: 591-5.
18. SMITH ME, STONE LA, ALBERT PS et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993: 33: 480-9.
19. STONE LA, ALBERT PS, SMITH ME et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995: 45: 1808-14.
20. STONE LA, FRANK JA, ALBERT PS et al. The effect of Interferon Beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995: 37: 611-19.
21. MILLER DH, ALBERT PS, BARKHOF F et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996: 39: 6-16.
22. FILIPPI M, HORSFIELD MA, TOFTS PS et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995: 118: 1601-12.
23. FILIPPI M, HORSFIELD MA, MORRISSEY SP et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994: 44: 635-41.